Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6652598 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A2PARP15PARP10SLC6A4 | |
| SCHEMBL9727913 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A2PARP15PARP10SLC6A4 | |
| SCHEMBL9727920 | 0.74 | SLC6A3 (0.38) | SLC6A3SLC6A2PARP15PARP10SLC6A4 | |
| SCHEMBL2727898 | 0.73 | SLC7A5 (0.47) | SLC6A3PARP15PARP10CTSC | |
| SCHEMBL2727900 | 0.73 | SLC7A5 (0.47) | SLC6A3PARP15PARP10CTSC | |
| SCHEMBL6193388 | 0.72 | PARP15 (0.36) | SLC6A3SLC6A2PARP15PARP10SLC6A4 | |
| Hydrochloric Acid SCHEMBL6751544 | 0.70 | PARP15 (0.36) | SLC6A3SLC6A2PARP15PARP10SLC6A4 | |
| SCHEMBL27594652 | 0.70 | PARP15 (0.36) | SLC6A3SLC6A2PARP15PARP10SLC6A4 | |
| SCHEMBL3659943 | 0.69 | PARP15 (0.44) | SLC6A3SLC6A2PARP15PARP10CTSC | |
| SCHEMBL1696694 | 0.68 | CYP2C19 (0.52) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421107-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | claimed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | claimed |
| WO-2003011896-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| EP-1421107-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | disclosed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | disclosed |
| WO-2003011896-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | disclosed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | disclosed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | disclosed |